Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Conagra Brands Inc (CAG) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Conagra Brands IncTrade
Regeneron Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Conagra Brands Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Conagra Brands Inc trades at $14.87 (market cap $7.07B), while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 11.8× Conagra Brands Inc's market cap, and Conagra Brands Inc pays the higher dividend (8.29%). Which is the better fit depends on your goals.

CAGREGN
Market Cap
$7.07B$83.19B
Sector
Consumer StaplesHealth
52-Week High
$20.02$812.27
52-Week Low
$12.58$555.51
Enterprise Value
$14.12B$77.90B
Dividend Yield
8.29%0.47%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Conagra Brands Inc

Conagra Brands (CAG) trades at $15.11, up 1.75% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. Fundamentally, the company reported strong 2025 results with $11.6B revenue and $1.15B net income, but faces challenges with negative margins projected for 2026. Recent developments include a 50% dividend cut to $0.18 and new leadership appointments under CEO John Brase, who recently purchased 35,000 shares.

The outlook remains cautious despite attractive valuation metrics (P/E 10.06, P/S 0.64). While analyst consensus leans Hold (62.5%), the stock trades above the $13.67 target. Key risks include persistent inflation pressure, declining sales, and margin compression. The dividend reduction provides financial flexibility but signals ongoing turnaround challenges.

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.

Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Conagra Brands Inc

Conagra Brands is a packaged food company that operates predominantly in the United States (over 90% of revenue and profits). It has a significant presence in the freezer aisle, with brands such as Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Other popular brands include Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, Wish-Bone, and Chef Boyardee. While the majority of revenue is sold into the U.S. retail channel, 9% of fiscal 2022 sales were to the food-service channel, down from 11% in fiscal 2019 due to the pandemic.

Read more on CAG

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN